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Gene delivery to, and gene targeting in, stem cells would 
be a highly enabling technology for basic science and 
biomedical application. Adeno-associated viral (AAV) 
vectors have demonstrated the capacity for efficient 
delivery to numerous cells, but their application to stem 
cells has been limited by low transduction efficiency. 
Due to their considerable advantages, however, engi-
neering AAV delivery systems to enhance gene delivery 
to stem cells may have an impact in stem cell biology 
and therapy. Therefore, using several diverse AAV capsid 
libraries—including randomly mutagenized, DNA shuf-
fled, and random peptide insertion variants—we applied 
directed evolution to create a “designer” AAV vector with 
enhanced delivery efficiency for neural stem cells (NSCs). 
A novel AAV variant, carrying an insertion of a selected 
peptide sequence on the surface of the threefold spike 
within the heparin-binding site, emerged from this evo-
lution. Importantly, this evolved AAV variant mediated 
efficient gene delivery to rat, mouse, and human NSCs, 
as well as efficient gene targeting within adult NSCs, and 
it is thus promising for applications ranging from basic 
stem cell biology to clinical translation.
Received 14 August 2010; accepted 26 November 2010; published online 
11 January 2011. doi:10.1038/mt.2010.287
IntroductIon
Stem cells—defined by the hallmark properties of self-renewal, 
i.e., the capacity to expand, maintain themselves in an undiffer-
entiated state, as well as differentiation into one or more special-
ized lineages—have considerable biomedical potential. However, 
better approaches must be developed to control their behavior. 
Gene delivery can serve as a valuable tool for numerous appli-
cations, including modulating stem cell fates by up-/down-
regulating specific genes, developing stem cell–based models of 
human disease, and tracking of stem cells or their progeny upon 
 implantation in vivo.1–2
Current methods to mediate gene delivery to stem cells include 
plasmid- and viral vector-mediated delivery. Plasmid-based gene 
transfer offers typically transient gene expression and a large carry-
ing capacity;3 however, current plasmid delivery systems for stem 
cells can suffer from low transfection efficiency.4 Alternatively, 
viral vectors based on retroviruses and lentiviruses offer high 
infectivity and stable gene expression and have been extensively 
employed in stem cell studies for genetic marking, protein or 
RNA overexpression, and targeted knock-down of endogenous 
gene expression.5,6 However, in some cases transient expression 
is desirable, such as for the temporary overexpression of regula-
tory signals to manipulate stem cells.7–9 Furthermore, insertional 
mutagenesis is a concern for potential downstream clinical appli-
cation of retroviruses.10 Adenoviral vectors also have potential 
for efficient delivery and transient gene expression in stem cells,11 
though the most commonly used adenoviral vectors carry numer-
ous virally-encoded factors that may perturb cell function.12 An 
efficient vector that mediates transient gene expression in stem 
cells may therefore have utility in the field.
In addition to gene delivery, the capacity for gene targeting via 
homologous recombination at specific loci in a mammalian stem 
cell genome has many potential applications, including basic inves-
tigation of processes of organismal development and mechanisms 
of human disease, the targeted introduction of genetic material 
into a genome without insertional mutagenesis, and therapeutic 
gene correction.13 However, plasmid-mediated gene targeting is 
typically very inefficient. Recent approaches that use zinc finger 
nucleases to enhance gene targeting efficiencies are highly prom-
ising, though they require engineering a new zinc finger nuclease 
for each new locus one would like to manipulate.14,15
Adeno-associated virus (AAV) is a parvovirus with a 4.7 kb 
single-stranded DNA genome containing two genes (rep and 
cap), and vectors based on AAV have proven safe and effective 
for clinical application.16–18 Exposure to AAV results in persistent, 
latent infection in a broad range of both dividing and nondividing 
cells.19,20 Additionally, Russell and colleagues have demonstrated 
that AAV vector genomes can mediate homologous recombination 
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with target sequences in a cellular genome at efficiencies 103–104-
fold higher than plasmid constructs.21 This capability has been 
successfully applied to cells that AAV can effectively transduce, 
including fibroblasts and recently mesenchymal stem cells, which 
has led to the development of new animal models of human dis-
ease.22,23 Although AAV-mediated gene expression and targeting 
would be effective tools for stem cell studies, AAV vectors are 
unfortunately extremely inefficient for gene delivery numerous 
stem cell types.24,25 Therefore, the development of new AAV vari-
ants capable of efficient stem cell infection may have impact in 
stem cell biology and regenerative medicine.
Embryonic neural stem cells (NSCs) are centrally involved 
in the development of the nervous system,26 and adult NSCs 
play a fundamental role in learning and memory and may yield 
new therapies for neurodegenerative disorders.27 However, AAV 
is extremely inefficient on NSCs.25 Our recent work highlights 
the potential of directed evolution to create new viruses with 
enhanced gene delivery properties.18,28–31 In this approach, we gen-
erate large (~107) and highly diverse libraries of viral variants, and 
the application of an evolutionary pressure—such as the ability to 
infect a stem cell—selects for the “fittest” variants. Importantly, 
this general approach can yield successful variants in the absence 
of mechanistic knowledge of which step(s) in the viral entry path-
way—such as cell surface binding, intracellular trafficking, and/or 
nuclear entry—pose(s) the most substantial barrier to infection. 
In this study, we have applied directed evolution to create a novel 
AAV vector with the capacity for high efficiency gene delivery 
to adult rat NSCs, and this variant was also efficient in murine 
and human NSCs. Furthermore, this high delivery efficiency was 
applied to enhance gene correction frequencies in NSCs, poten-
tially providing a tool with potentially strong utility for both basic 
biology and biomedical application.
results
AAV library generation
We found that several wild-type AAV serotypes (2, 4, 5, 6, and 8) 
exhibited low transduction efficiencies [0.7–9.7% with multiplic-
ity of infection (MOI) 105] of NSCs (Figure 1a), as previously 
described.24,25 These results motivated pursuing directed evolu-
tion for the development of novel AAV variants that can more 
effectively infect NSCs. Three large (>106 independent clones 
each), diverse libraries were used: (i) random viral chimeras cre-
ated via pairwise DNA shuffling of the AAV2 cap gene with that 
of AAV4, 5, 6, or 8, (ii) AAV2 capsid variants with a random 7 
amino acid sequence inserted into a key loop region,32 and (iii) 
random point mutants of the cap gene of AAV2 generated via 
error prone PCR18 (Figure 1b). Libraries were packaged as previ-
ously described to generate a large pool of AAV mutant capsids 
containing the genome encoding those mutants.18 NSCs, isolated 
from the hippocampus of adult Fisher 344 rats,27 were infected by 
each AAV library, adenovirus serotype 5 was added to induce the 
replication and rescue of the “successful” AAV variants, the sur-
viving AAV cap genes were recovered by PCR and cloned into the 
AAV genome plasmid, and the next generation library was pack-
aged. After four such iterative selection steps, the resulting viral 
pool was subjected to additional mutagenesis by error prone PCR 
on the selected cap genes, followed by further iterative selections 
(Figure 1b). During the three rounds of evolution and 10 selec-
tion steps, the variant pool became progressively more infectious 
than wild-type AAV2 (data not shown).
AAV variants selected through directed evolution
DNA sequencing analysis revealed that the final pools con-
tained seven AAV variants: two shuffled, three peptide-inserted, 
and two error prone clones (Figure 2, Table S1). Interestingly, 
the shuffled clones (r3.1, r3.10) were composed of AAV2 and 
AAV5 sequences, with additional point mutations located on 
the viral surface. Although AAV2 and 5 were less efficient than 
AAV4 and AAV6 (Figure 1a), the low efficiencies of AAV4 and 
AAV6 [<10% green fluorescent protein positive (GFP+) NSCs 
at a MOI 105] may be insufficient to enable wild-type cap4 and 
cap6 to be represented in the selected pool. Furthermore, com-
binations of fragments of cap4 and cap6 with cap2 likely yield 
gene delivery properties that are distinct from the parental cap 
4 and cap6. In addition, two peptide insertions were present in 
three clones (r3.3, r3.21, r3.45), which also carried several point 
mutations.
Figure 1 rationale and strategy for engineering novel AAV variants. 
(a) Rat neural stem cell (NSC) infection with wild-type adeno-associated 
viral (AAV) 2, 4, 5, 6, and 8. Cells were infected by addition of green fluo-
rescent protein (GFP) vectors at a multiplicity of infection (MOI) of 105. 
Cells were incubated with virus for 24 hours, followed by analysis of GFP 
expression by flow cytometry after an additional 24 hours. Even at this 
high MOI, the highest gene delivery efficiency was <10%. (b) Directed 
evolution of novel AAV vectors for enhanced NSC infection: (1) plasmid 
libraries were generated by DNA shuffling, peptide insertion, and error 
prone PCR [error prone (EP)], (2) viral libraries were packaged, (3) NSCs 
were infected with libraries, followed by adenovirus addition, (4) the 
resulting amplified AAV variants were harvested, and (5) viral genomes 
were isolated and cloned. The cycle of steps (2)–(5) was iterated (7) with 
(6) additional EP PCR after the fourth and seventh cycles. Newly evolved 
clones were used to produce recombinant virus (8) and analyzed for the 
ability to infect NSCs (9), and the final clone was selected (10).
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novel AAV variant with enhanced properties  
for nsc infection
These capsid mutants were used to package recombinant vec-
tor encoding GFP driven by a cytomegalovirus (CMV) pro-
moter, which revealed that six of the variants exhibited similar 
or slightly improved efficiencies compared to AAV2 or AAV5 
(Supplementary Figure S1). Additional rounds of selection 
would likely have eliminated these variants to yield a domi-
nant clone.30 In stark contrast, however, the variant AAV r3.45 
mediated high delivery efficiencies (Figure 3a–f). At MOI of 
103, 104, and 105, AAV r3.45 infected 14.4–50 fold more cells 
relative to AAV2 and AAV5 (Figure 3d–f). Importantly, 7 days 
after infection with AAV r3.45, nearly 100% of GFP+ cells 
maintained expression of the neural progenitor marker nes-
tin (Figure 4a), indicating that infected cells remained in an 
immature state.
AAV r3.45 carried an insertion of LATQVGQKTA (where LA 
and A are linker residues) at amino acid 587 with an additional 
V719M mutation (Figure 4b). The inserted peptide likely lies on 
the surface of the threefold spike within the heparin-binding site 
(Figure 4c,d), and the point mutation is also surface-exposed. 
AAV r3.3, which harbored the same peptide insertion but with 
three different point mutations (i.e., V118I, S537C, and G599S), 
exhibited considerably lower packaging titers and infectivities 
than AAVr3.45, indicating that slight capsid modifications can sig-
nificantly impact viral properties (Figure 1 and Supplementary 
Figure S1). Importantly, AAV r3.45 was additionally highly 
infectious for both murine and human NSCs (Figure 5a–c). 
It was also infectious in several other nonpermissive cell types 
(Supplementary Figure S2), though not in human or murine 
embryonic stem cells (Supplementary Figure S3a,b), indicating 
that its benefits are somewhat cell selective. However, despite its 
lack of cell specificity, its enhanced gene delivery to cultured NSCs 
from three different species met the goals of this study and indi-
cates that AAV r3.45 may be used in a variety of stem cell applica-
tions, such as transient expression of factors or gene targeting to 
generate knock-ins/-outs for basic investigation or the develop-
ment of disease models.
To investigate the roles of the peptide insertion and the 
V719M mutation for the enhancement of NSC infection, the 
V719M mutation was reversed via site-directed mutagenesis, 
and the resulting variant, which contains the peptide insertion 
without the V719 mutation, was packaged and employed to infect 
NSCs. This correction of the V719M mutation did not influ-
ence the infectivity, indicating the peptide sequence displayed 
on the AAV r3.45 capsid is critical to enhance gene delivery to 
NSCs (Supplementary Figure S4). However, although a BLAST 
search (http://www.ncbi.nlm.nih.gov/BLAST/) revealed that 
the inserted sequence bears sequence similarity to a number of 
intracellular enzymes (e.g., Halobacterium salinarum naphthoate 
synthase), it was not similar to any secreted mammalian or viral 
capsid proteins.
To determine whether this variant may still use heparan 
sulfate as its primary receptor, despite its peptide insertion 
within the AAV2 heparin-binding domain,33 we compared 
the heparin affinity of AAV r3.45 to that of wild-type AAV2. 
Purified AAV2 or AAV r3.45 was loaded onto a heparin col-
umn and eluted with a series of increasing NaCl concentra-
tion (150–750 mmol/l, and 1 mol/l), and a portion of each 
fraction was added to 293T cells to quantify infectious virus 
(Supplementary Figure S5). Similar to previous reports,18,29 
fractions from 450 to 550 mmol/l NaCl contained the majority 
of wild-type AAV2. However, AAV r3.45 eluted in a sharp peak 
between 350 mmol/l and 450 mmol/l, indicating that heparan 
sulfate may still be primary receptor, but its affinity to heparan 
sulfate may be slightly altered.
enhanced gene correction frequency  
with newly designed AAV variant
We next assessed the capacity of AAV r3.45 to mediate gene 
correction in NSCs. GFP cDNA harboring a stop codon (mut-
GFP1) was introduced into adult rat NSCs using a lentiviral 
vector. In parallel, a promoter-less GFP with a distinct stop 
codon (mutGFP2) was packaged into a recombinant AAV vec-
tor (Figure 6), and the resulting gene targeting construct carry-
ing mutGFP2 had 586 nucleotides of homology upstream and 
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Figure 2 schematic maps of novel adeno-associated viral (AAV) variants. AAV r3.1 denotes the first AAV clone isolated after three rounds of 
evolution. The gray and blue coloring depicts AAV2 capsid and AAV5 capsid regions, respectively. In the peptide-inserted vectors, “LA” and “A” were 
inserted as linkers.
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1,548 nucleotides downstream of the amber mutation in mut-
GFP1. Upon infection of NSC-mutGFP1 cells with the target-
ing vector, recombination with the integrated lentiviral vector 
corrected the amber mutation in mutGFP1, resulting in fluores-
cent NSCs (Figure 7a). Importantly, AAV r3.45 demonstrated 
a significantly improved capacity (six- to tenfold) to repair the 
single-base pair mutation in NSC-mutGFP1 cell line compared 
to AAV2 and AAV5 (Figure 7b, Table S2). Controls, includ-
ing the infection of NSC-mutGFP1 cell lines by AAV CMV Luc 
(Figure 7c) and naive NSCs infected by the targeting vectors 
(data not shown), did not yield GFP expression, verifying the 
specificity of the process.
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Figure 5 enhanced neural stem cell tropism of AAV r3.45. Comparison of transduction efficiencies of adeno-associated virus (AAV) r3.45 versus 
AAV2 for (a) murine neural stem cells (NSCs), (b) human fetal NSCs, and (c) human neural progenitor cells. Cells were infected at a multiplicity of 
infection (MOI) of 103, 104, and 105, and green fluorescent protein (GFP) expression was analyzed via flow cytometry 48 hours after infection.
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Figure 3 neural stem cell (nsc) transduction by adeno-associated virus (AAV) r3.45. (a) Phase-contrast microscopy and (b) fluorescence micros-
copy of cells infected by AAV r3.45 [genomic multiplicity of infection (MOI): 105] shows a high level of transduction. Bar = 100 µm. (c) Histogram of 
green fluorescent protein (GFP)-expressing cells: MOI 103 (red), MOI 104 (green), MOI 105 (blue). Efficiencies of recombinant AAV2, AAV5, and AAV 
r3.45 were quantified by flow cytometry at (d) MOI 103, (e) 104, and (f) 105.
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Figure 4 neural stem cells (nscs) infected with adeno-associated virus (AAV) r3.45 remain undifferentiated. (a) Seven days after infection with 
AAV r3.45, immunostaining revealed that the majority of green fluorescent protein expressing cells were positive for nestin, a neural progenitor cell 
marker. Bar = 20 µm. (b) Schematic representation of the peptide sequence, point mutation, and heparin-binding residues of AAV clone r3.45. (c) 
Structural model of a VP3 subunit of AAV r3.45, as well as (d) the full capsid. The color scheme for panels b–d is: V719M (blue), peptide sequence at 
amino acid 587 (red), and heparin-binding residues (R585/R598) (purple).
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Verification of gene correction
To confirm the GFP gene correction, GFP+ cells were isolated by 
fluorescence-activated cell sorting 14 days after AAV infection, 
and cellular genomic DNA was subjected to PCR to amplify the 
GFP sequence specifically from the lentiviral vector. Sequence 
analysis of 24 cloned PCR fragments revealed 19 corrected 
sequences (79.2%), with the five uncorrected sequences presum-
ably resulting from NSCs infected with multiple lentiviral vectors 
(Figure 7d,e). In parallel, sorted cells were expanded for an addi-
tional 26 days (total 40 days after AAV infection), and ~94.5% of 
cells maintained GFP and nestin expression (Figure 8).
dIscussIon
AAV is a highly versatile vector with a broad-host range; how-
ever, its delivery efficiency to certain cell types, including neu-
ral or embryonic stem cells, is low.24,25 One potential reason is a 
lack of necessary cell surface receptors for a given serotype (e.g., 
heparan sulfate, integrins), resulting in low attachment affinity 
and cellular internalization. Alternatively, intracellular trafficking 
pathways can also pose barriers, as for example nuclear trafficking 
of AAV is a key rate-limiting step for AAV transduction of some 
cell types such as murine fibroblasts.34 Additionally, noncapsid 
related limitations including double-stranded DNA synthesis can 
compromise AAV-mediated gene expression.35 Our finding that 
a short peptide insertion into the exterior surface of AAV2 can 
substantially increase delivery efficiency implicates capsid-related 
steps such as receptor binding or intracellular trafficking as poten-
tial barriers. 
The slight shift in the heparin affinity of this variant AAV 
r3.45 (Supplementary Figure S5) may correspond to a significant 
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Figure 7 Adeno-associated virus (AAV) r3.45-mediated gene correction by homologous recombination with a nonfunctional green fluores-
cent protein (GFP) expressed in neural stem cells (nsc) and verification of gene correction. (a) Immunostaining of GFP+, gene-corrected NSC-
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modulation of heparan sulfate binding, potentially due to the 
inserted peptides’ conformational alteration of a key exposed loop 
of the heparin binding domain. However, the fact that the major-
ity of AAV r3.45 still eluted at relatively high NaCl concentrations 
indicates that this variant may still utilize heparan sulfate as its 
primary receptor. In addition, the LATQVGQKTA peptide may 
thus contribute to binding to an alternate secondary receptor or 
to an intracellular transduction step. Future studies may elucidate 
this mechanism of action.
The central goal of the directed evolution in this study was to 
create novel vectors that can better infect NSCs; therefore, posi-
tive selection was applied for enhanced adult rat NSC transduc-
tion, and negative selection was not applied to remove tropism 
for other cell types. The approach successfully yielded a novel 
AAV variant with significantly enhanced infectivity of not only 
adult rat but also mouse and two human NSCs. As anticipated this 
enhanced infectivity was not accompanied by specificity for NSCs, 
as AAV r3.45 was more efficient than AAV2 for several cell types, 
including primary human astrocytes (Supplementary Figure S2). 
Accordingly, in vivo AAV r3.45 would be anticipated to transduce 
NSCs as well as other surrounding cell types (i.e., astrocytes, olio-
godendrocytes).  However, alternative selection strategies could 
be implemented to achieve specificity of delivery.
The development of an efficient vehicle for transient gene 
expression in neural stem cells has applications ranging from the 
overexpression of factors to induce the differentiation or “pro-
gramming” of neural stem cells, as well as potentially expression 
of defined transcription factors to reprogram cells.36,37 Moreover, 
enhanced transduction and gene targeting capabilities in NSCs 
may facilitate stem cell biology and regenerative medicine 
investigations, potentially including the introduction of defined 
mutations for basic studies, generation of reporter cell lines, and 
therapeutic gene correction. By yielding a variant with high effi-
ciency gene delivery and gene targeting in NSCs, directed evolu-
tion is further established as a powerful approach to engineer 
novel capabilities into AAV vectors.18,28–31 Further reverse engi-
neering analysis of the gene delivery mechanisms of this variant 
may elucidate mechanisms that limit gene delivery in stem cells, 
as well as the other cell types efficiently infected by this variant. 
Finally, this general approach may in the future be applied to 
other cell and stem cell types, thereby extending the utility of 
AAV to additional biotechnology and biomedical applications.
MAterIAls And Methods
NSC culture. Adult rat NSCs, isolated from the hippocampal region of 
6-week-old female Fisher 344 rats as described,27,38 were cultured on tissue 
culture polystyrene dishes previously coated with poly-ornithine (10 µg/ml) 
(Sigma-Aldrich, St Louis, MO) and mouse laminin (5 µg/ml) (Invitrogen, 
Carlsbad, CA), in Dulbecco’s modified Eagle’s medium (DMEM)/F-12 
(1:1) (Invitrogen) containing N-2 supplement (Invitrogen) and 20 ng/ml 
of recombinant human fibroblast growth factor 2 (Peprotech, Rocky Hill, 
NJ). Under these conditions, nearly 100% of cells express nestin and Sox2 
(data not shown). Every 2–3 days (>60% confluency), cells were split into 
a fresh dish by mechanical dissociation using polished pasteur pipettes. 
Adult murine NSCs (a kind gift of Prof Andrew Wurmser, University of 
California at Berkeley) were cultured in DMEM with 20 ng/ml of recom-
binant fibroblast growth factor 2 (Peprotech) and 8 μg/ml of heparin. 
Human fetal NSCs (13 weeks of gestational age) were derived from the 
telencephalon (HFT13) as previously described39 and were cultured in 
DMEM/F-12 containing N-2 supplement, 20 ng/ml of fibroblast growth 
factor 2, 8 μg/ml of heparin (Sigma-Aldrich), and 10 ng/ml of leukemia-
inhibitory factor (Chemicon, Temecula, CA). Human neural progenitor 
a b c
fed
Figure 8 Maintenance of the undifferentiated state of gene-corrected, green fluorescent protein (GFP)-expressing neural stem cells 35-days 
postinfection. (Nestin: red, GFP: green). The nuclei of cells were co-stained with TOPRO3 (blue). Bar = 50 µm. (a–c: ×200, d–f: ×50, a,d: GFP, b,e: 
nestin/TOPRO, c,f: GFP/nestin/TOPRO3).
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cells were derived from a variant of the human embryonic stem cell line 
BG01 (BresaGen, Athens, GA), BG01V2, using the stromal derived induc-
ing activity involving a co-culture system of human embryonic stem cells 
and mouse stromal cell line PA6 (Riken BioResource Center Cell Bank, 
Tsukuba, Japan) (Vazin et al. manuscript in preparation) and were cul-
tured in DMEM/F-12 supplemented with N-2, 20 ng/ml basic fibroblast 
growth factor, 20 ng/ml epidermal growth factor (Invitrogen), and 50 U/
ml Penicillin/Streptomycin.
Plasmid library construction. Random mutagenesis libraries were 
generated by subjecting cap genes from AAV2 to error prone PCR as 
previously described.18 Peptide display libraries were generated simi-
lar to previous reports.32,40 Briefly, a unique Avr II was introduced into 
pSub2Cap2 between amino acid 587 and 588 by PCR mutagenesis. A 
random 21 base pair oligonucleotide [5′-GGAGGGCTAGCA (NNK)7 
GCTAGCAAAAGCGGGGGGAGAGTGAGG-3′] was annealed to an 
antisense primer 5′-CCTCACTCTCCCCCCGCT-3′, followed by synthe-
sis of the second strand. The resulting dsDNA inserts were digested with 
Nhe I and ligated into the unique Avr II site of pSub2Cap2. Pairwise DNA 
shuffling libraries of AAV2 with AAV4, AAV5, AAV6, or AAV8 (AAV2-
AAV4, AAV2-AAV5, AAV2-AAV6, and AAV2-AAV8) were generated 
by PCR amplification of cap genes from AAV2, AAV4, AAV5, AAV6, 
and AAV8 and followed by insertion into pSub2. Each viral gene was 
then amplified via PCR, and DNA shuffling was performed as previously 
described.41,42 Briefly, DNase I digestion of equimolar amounts of PCR-
amplified cap genes yielded fragments ranging from 50 to 500 base pair in 
size. Fragments were gel purified and reassembled without primers in the 
following conditions: 96 °C, 3 minutes; 40 cycles of 94 °C, 55 °C, and 72 °C; 
and 72 °C, 10 minutes. Assembled fragments were further amplified by 
PCR and cloned into pSub2 for replication competent AAV production.
Selection of viral libraries. The plasmid library was used to package rep-
lication competent AAV as previously described,18,43 and the resulting 
viral libraries were then harvested as described.44 Virus was purified using 
OptiPrep (60%, wt/vol iodixanol) (Sigma-Aldrich) density gradient ultra-
centrifugation according to the manufacturer’s instructions, and genomic 
titers of AAV viral libraries were determined by quantitative real time 
PCR on a Bio-Rad iCycler (Bio-Rad, Hercules, CA) using a Taqman probe 
(Biosearch Technologies, Novato, CA).18
NSCs, seeded at a density of 6 × 105 per well in 6-well tissue culture 
plates coated with poly-ornithine/laminin one day prior to infection, were 
infected with either wild-type AAV2 or the AAV libraries at genomic MOIs 
of 10, 100, and 1,000. After a 24-hour exposure, cells were co-infected with 
adenovirus serotype 5 in fresh medium (i.e., DMEM/F12 + N2, fibroblast 
growth factor 2). Once cells exhibited cytopathic effect, after approximately 
two additional days of culture, they were lysed by three freeze/thaw steps, 
followed by the treatment with benzonase (1 unit/ml) (Sigma-Aldrich) 
at 37 °C for 30 minutes. Adenovirus was inactivated by incubating the 
viral lysates at 50 °C for 30 minutes. To quantify viral libraries rescued 
from the each selection, viral genomic DNA was extracted from DNase-
resistant particles. At each step, the total viral genomic DNA rescued was 
compared for the viral libraries versus wild-type AAV2.
Evolution of viral libraries. One round of evolution is defined as cap muta-
genesis followed by several selection steps, i.e., NSC infection and adenovirus 
rescue. After 3–4 selection steps, the rescued AAV cap genes were randomly 
mutated by error prone PCR as previously described.18 The resulting PCR 
products were digested with Hind III and Not I, and the fragments were ligated 
into pSub2 to create a new replication competent AAV plasmid library with 
at least 106 independent clones. Viral library packaging was then conducted 
by the calcium phosphate transient transfection method,18 and viral titration 
and purification were performed as with the initial library construction.
After the evolution was completed, AAV cap genes were extracted 
from the final pool of successful AAV variants, and genomic sequences 
were analyzed at the UC Berkeley DNA Sequencing Facility. The extracted 
viral genomes were amplified by PCR and inserted into the pXX2 Not 
I recombinant AAV (rAAV) packaging plasmid.22,33. Three-dimensional 
models of the VP3 subunit were generated using Swiss Model (http://
swissmodel.expasy.org) with the coordinates of AAV2 (Protein Databank 
accession no. 1LP3) supplied as template, and images were rendered in 
Pymol (http://pymol.sourceforge.net/) and Rasmol.
Heparin column chromatography. AAV r3.45 and AAV2 binding to hepa-
rin were analyzed as previously described.18,29 Briefly, ~1011 purified genomic 
particles of virus were loaded onto a 1 ml HiTrap heparin column (GE 
Healthcare Life Sciences, Pittsburgh, PA), which was previously equilibrated 
with Tris buffer (50 mmol/l, pH 7.5) containing 150 mmol/l NaCl. Elutions 
were performed with 0.75 ml of Tris buffer containing increasing increments 
of 50 mmol/l NaCl up to 750 mmol/l, followed by a 1 mol/l NaCl wash. Small 
fractions (75 μl) of each elution were added to 2.5 × 105 293T cells cultured in 
12-well dishes and employed to quantify the level of infectious virus present. 
Forty-eight hour postinfection, GFP expression was measured with Becton 
Dickinson fluorescence-activated cell sorting Caliber (Yonsei University 
College of Medicine Medical Research Center, Seoul, Korea).
NSC transduction. To test the infectivity of rAAV cap clones, vectors car-
rying cDNA encoding GFP were packaged using the transient transfection 
method. Briefly, an equal mass (17 µg) of three plasmids—a AAV helper 
plasmid (carrying a cap variant), CMV GFP vector plasmid containing 
ITR (pAAV CMV GFP SN), and pHelper plasmid—were transfected via 
calcium phosphate into AAV293 cells,18,27 and viral vectors were harvested 
and purified as described above. Genomic titers of each rAAV vector were 
determined by quantitative PCR.
One day prior to AAV infection, NSCs were plated onto 24-well 
dishes at a density of 30,000 cells/well. On day 1, cells were infected by 
the rAAV clones at genomic MOIs (103, 104, and 105) and incubated for 
additional 48 hours before analysis. The resulting transduction efficiencies 
of the individual rAAV variants on rat and murine NSCs were quantified 
with a Beckman–Coulter EPICS XL flow cytometer (UC Berkeley Cancer 
Center, Berkeley, CA) and compared to those of AAV2 and AAV5, which 
were chosen as controls since the two shuffled clones that emerged from 
the evolution carried fragments from AAV cap2 and AAV cap5 (Figure 1). 
Human NSC and neural progenitor cell transduction efficiencies were 
quantified with a Becton Dickinson fluorescence-activated cell sorting 
Caliber (Yonsei University College of Medicine Medical Research Center) 
and Beckman–Coulter FC 500 flow cytometer (Berkeley Stem Cell Center, 
Berkeley, CA), respectively.
Immunofluorescence staining. To analyze AAV r3.45 infection of undif-
ferentiated NSCs, and the effects of AAV infection on NSC differentiation, 
immunostaining for nestin (undifferentiated NSCs), β-III-tubulin (neu-
rons), and glial fibrillary acidic protein (astrocytes) was conducted.31 NSCs 
were seeded onto 8-well chamber slides and infected as indicated above. 
At 48 hours postinfection, cells were fixed in 4% paraformaldehyde for 15 
minutes and blocked with 5% goat serum in 0.3% Triton X-100/phosphate-
buffered solution for 30 minutes at room temperature. Cells were incu-
bated overnight at 4 °C with primary antibodies. For nestin/β-III-tubulin 
co-staining, rabbit anti-rat nestin (1:500 dilution; Abcam) and mouse 
anti-β-III-tubulin (1:500 dilution; Sigma-Aldrich), and, for nestin/glial 
fibrillary acidic protein costaining, mouse anti-rat nestin (1:1,000 dilution; 
BD Biosciences) and guinea-pig anti-glial fibrillary acidic protein(1:1,000 
dilution; Advanced ImmunoChemical, Long Beach, CA) were used. 
Subsequently, cells were rinsed thoroughly and stained with secondary flu-
orescent-conjugated antibodies, including goat anti-rabbit Alexa 546 (1:250 
dilution; Molecular Probes, Carlsbad, CA), goat anti-mouse Cy5 (1:250 
dilution; Jackson ImmunoResearch, West Grove, PA), goat anti-mouse Cy3 
(1:250 dilution; Jackson ImmunoResearch), or goat anti-guinea-pig Cy5 
(1:250 dilution; Jackson ImmunoResearch). Stained cells were imaged by 
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fluorescence confocal microscopy (Leica Microsystems, Bannockburn, IL) 
or fluorescence microscopy (Nikon ECLIPSE TE2000-E, Nikon, Melville, 
NY, or Olympus IX50, Olympus America). When amplifying GFP signals, 
rabbit anti-GFP (1:2,000 dilution; Invitrogen, Center Valley, PA) and goat 
anti-rabbit Alexa 488 (1:250 dilution; Invitrogen) were used as primary and 
secondary antibodies, respectively.
Generation of mutant GFP NSC line. An internal ribosome entry site and 
puromycin resistance gene cassette was cloned into the Eco RI and Xho I 
sites of pFUGW (a kind gift from David Baltimore, California Institute of 
Technology, Pasadena, CA), which contains an enhanced GFP gene under 
the control of human ubiquitin-C promoter.45 To insert an amber stop 
codon (TAA) into the GFP sequence, the substitution of “C” to “A” was 
introduced 603 nucleotides from the 5′ end of GFP via QuikChange site-
directed mutagenesis. The inserted point mutation was verified by DNA 
sequencing analysis.
A stable NSC cell population expressing the amber mutant GFP (NSC-
mutGFP1) was generated by infection with lentiviral vector carrying the 
defective GFP. Briefly, 10 µg of pFUG carrying UB-mutGFP1-internal 
ribosome entry site and puromycin resistance gene cassette, 5 µg of pMDL 
g/p PRE, 3.5 µg of pcDNA3 IVS vesicular stomatitis virus G, and 1.5 µg of 
pRSV Rev, were transfected into HEK 293T cell lines (>70% confluency) 
by the calcium/phosphate transient transfection method.46 The lentiviral 
vector was harvested and concentrated by ultracentrifugation (L8-55M 
Ultracentrifuge; Beckman–Coulter, Brea, CA), followed by resuspension 
in 100 µl of phosphate-buffered solution with 20% sucrose. Infectious 
titer, determined as previously described,47 was 1.58 × 107 ± 4.66 × 106 IU/
ml. NSCs were seeded onto 6-well tissue culture plates at a density of 3 × 
105 cells/well and infected by 0, 1, 3, 5, 10, or 20 μl of the lentiviral vector. 
After puromycin selection,48 the well in which 70–80% of cells survived 
was expanded for further analysis. The integration of lentiviral genomes 
was verified by cellular genomic DNA extraction, PCR amplification, and 
sequencing analysis of the PCR products. Importantly, GFP fluorescence 
was not detected in the mutGFP1 NSC cells, as confirmed by both flow 
cytometry and immunostaining against GFP.
Gene targeting assay. A point mutation (G to T) was inserted 16 nucle-
otides from the 5′ end of GFP to yield a defective GFP open reading frame 
(mutGFP2). Subsequently, pFUG was digested with Bam HI and Xho I, 
and the mutGFP2-internal ribosome entry site and puromycin resistance 
gene cassette was subcloned into an AAV vector plasmid (i.e., pAAV CMV 
GFP SN), where CMV GFP was excised by Bam HI and Xho I, such that 
the resulting targeting vector lacked a promoter. This genetic construct was 
packaged into the AAV2, AAV5, and AAV r3.45 capsids, and AAV r3.45 
carrying luciferase driven by CMV promoter was used as a negative con-
trol. All viral vectors were harvested and purified as described earlier.
NSCs were seeded onto 24-well tissue culture plates at a density of 
50,000 cells/well 1 day prior to AAV infection. Each AAV targeting vector 
was added to the NSCs at a genomic MOI of 5 × 105, and the medium was 
replaced 24 hours later. Infected NSCs were analyzed by flow cytometry 
(Cytomics FC500; Beckman–Coulter) 3 days after infection, and the 
percentage of GFP+ cells was scored as the gene targeting frequency.
Cell sorting and sequencing. Cells continuously cultured for 14 days 
after AAV r3.45 infection were sorted with a Cytopeia Influx Sorter (UC 
Berkeley Cancer Center, Valencia, CA) to isolate FL1 (i.e., GFP) positive 
cells. A fraction of the sorted cells was used for DNA sequencing analysis, 
and the remainder was expanded for an additional 26 days, at which time 
94.5% still expressed GFP (data not shown). For DNA sequencing analy-
sis, cellular genomic DNA was extracted with the QIAamp DNA Micro Kit 
(Qiagen) and amplified by using 5′-GCGGCAAGAACCCAAGGTCT-3′ 
and 5′-CGGCTTCGGCCAGTAACGTT-3′ primers. To specifically 
amplify a fragment from the lentiviral vector and exclude amplification 
from the AAV viral genome, the forward primer was designed to amplify 
from the half part of UB promoter in the targeted site, which existed only 
in the lentiviral vectors. The resulting PCR products were cloned using 
the StrataClone PCR cloning kit (Stratagene, La Jolla, CA), and individual 
clones were sequenced to confirm the gene correction.
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Figure S1. Percentages of GFP positive neural stem cells transduced 
by recombinant vectors pseudotyped with capsids from AAV2, AAV5, 
and selected AAV variants.
Figure S2. Comparison of transduction efficiencies of selected AAV 
variants with wtAAV2 on a panel of cell types.
Figure S3. Comparison of transduction efficiencies of AAV r3.45 
versus AAV2.
Figure S4. Comparison of transduction efficiencies of original AAV 
r3.45 (peptide insertion + V719M point mutation) versus modified 
AAV r3.45 (peptide insertion only, V719M correction).
Figure S5. Heparin column chromatograms for wild-type AAV2 and 
AAV r3.45 to investigate the heparin affinity of AAV r3.45.
Table S1. Genomic and infectious titers of wild-type AAV serotypes 
and AAV variants. Infectious titers were obtained from HEK 293T cell 
infection.
Table S2. Genomic titers of gene targeting vectors.
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